Australia is eagerly awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://deaconmdmq160349.tribunablog.com/novo-nordisk-s-retatrutide-australia-a-potential-solution-for-obesity-treatment-57572850